4.75
+0.29(+6.50%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
154
First IPO Date
July 10, 2020
| Name | Title | Pay | Year Born |
| Dr. Yu Wang | Founder, Chief Executive Officer, Chief Technology Officer & Executive Director | 2.53M | 1968 |
| Mr. Hyun Chul Jung | Founder & Chief Strategy Officer | 658,494 | 1963 |
| Mr. Zheng Tan | Executive Chairman | 2.61M | 1978 |
| Mr. Jian Zhang | Senior Vice President | 0 | 1971 |
| Ms. Shui Bing Leung A.C.S. | Company Secretary | 0 | 1977 |
| Dr. Yu Zhang | Chief Scientist | 0 | 1965 |
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; and TCR-T cell series products to treat solid tumors. The company was founded in 2006 and is headquartered in Beijing, the People's Republic of China.